Targeting Activins to Treat Cachexia

Grant number: 1078907 | Funding period: 2018 - 2018

Completed

Abstract

This project will examine Activins, as contributing factors to the loss of lean and fat mass that is commonly observed in patients with advanced cancer, and evaluate the therapeutic prospects of administering novel engineered Activin inhibitors, to prevent Activin-induced disease.

Related publications (4)

TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass

A Hagg, S Kharoud, G Goodchild, CA Goodman, JL Chen, RE Thomson, H Qian, P Gregorevic, CA Harrison, KL Walton

2020-11-04

Inhibition of myostatin- and activin-mediated SMAD2/3 signaling using ligand traps, such as soluble receptors, ligand-targeting pr..

Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice

KL Walton, JL Chen, Q Arnold, E Kelly, M La, L Lu, G Lovrecz, A Hagg, TD Colgan, H Qian, P Gregorevic, CA Harrison

2019-08-06

In cancer, elevated activin levels promote cachectic wasting of muscle, irrespective of tumor progression. In excess, activins A a..

Molecular characterization of latent GDF8 reveals mechanisms of activation

RG Walker, JC McCoy, M Czepnik, MJ Mills, A Hagg, KL Walton, TR Cotton, M Hyvönen, RT Lee, P Gregorevic, CA Harrison, TB Thompson

2018-01-30

Growth/differentiation factor 8 (GDF8), or myostatin, negatively regulates muscle mass. GDF8 is held in a latent state through int..

Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease

JL Chen, KL Walton, A Hagg, TD Colgan, K Johnson, H Qian, P Gregorevic, CA Harrison

2017-06-27

The transforming growth factor-β (TGF-β) network of ligands and intracellular signaling proteins is a subject of intense interest ..

University of Melbourne Researchers

Paul Gregorevic